Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 26

Results For "Research"

2275 News Found

FDA grants breakthrough therapy designation to R-DXd for platinum-resistant ovarian and related cancers
Drug Approval | September 16, 2025

FDA grants breakthrough therapy designation to R-DXd for platinum-resistant ovarian and related cancers

Raludotatug deruxtecan is a specifically engineered, potential first-in-class CDH6-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo


Rona submits IND for GalNAc-conjugated siRNA targeting obesity
Drug Approval | September 16, 2025

Rona submits IND for GalNAc-conjugated siRNA targeting obesity

RN3161 is engineered to reduce fat while preserving lean mass, setting it apart from current treatment options


GAIASO appoints Dr. Tracey Brown as CEO
People | September 16, 2025

GAIASO appoints Dr. Tracey Brown as CEO

Dr. Brown brings extensive international experience in oncology and radiopharmaceutical development,


Goa to host historic 10th Ayurveda day on September 23
News | September 16, 2025

Goa to host historic 10th Ayurveda day on September 23

We are taking Ayurveda to the world as a sustainable healthcare solution: Union Minister Prataprao Jadhav


Prof. P K Prajapati assumes charge as Director of AIIA, New Delhi
People | September 16, 2025

Prof. P K Prajapati assumes charge as Director of AIIA, New Delhi

Prior to this appointment, he served as Vice-Chancellor of Dr. Sarvepalli Radhakrishnan Rajasthan Ayurved University, Jodhpur,


Libtayo plus chemotherapy demonstrates five-year survival benefit in advanced NSCLC
Clinical Trials | September 16, 2025

Libtayo plus chemotherapy demonstrates five-year survival benefit in advanced NSCLC

Late-breaking data presented at WCLC highlight significant and sustained improvements in overall survival, including more than doubling five-year survival rates compared to chemotherapy alone


FDA launches crackdown on deceptive drug advertising
Policy | September 16, 2025

FDA launches crackdown on deceptive drug advertising

The FDA is beginning rulemaking to close the “adequate provision” loophole


Novo Nordisk’s amylin therapy cagrilintide shows significant weight loss in phase 3 trial
Clinical Trials | September 16, 2025

Novo Nordisk’s amylin therapy cagrilintide shows significant weight loss in phase 3 trial

Cagrilintide represents a novel approach to obesity management